Current Status of Cell Culture Drug Resistance Testing (CCDRT)

1Larry M Weisenthal MD PhD and 2Peter Nygren MD PhD

1Weisenthal Cancer Group, 15140 Transistor Lane, Huntington Beach, CA 92649 and 2Departments of Clinical Pharmacology and Oncology, Uppsala University, Uppsala, Sweden; 2

Phone: 714-894-0011, Fax: 714-893-3658


Cell culture drug resistance testing (CCDRT) is purported to correlate with response to chemotherapy and/or with patient survival after chemotherapy. Advocates of CCDRT maintain that this information is of value in clinical drug selection, particularly in situations where there is a choice to be made between more than one acceptable drug regimen. Assays based on a cell proliferation or DNA synthesis endpoint were largely studied in the early to mid-1980s and are currently advocated chiefly for the identification of inactive drugs. Assays based on cell death as an endpoint were the subject of increasing study during the late 1980s and throughout the 90s. An extensive, diverse, and consistent literature documents the ability of cell death assays to identify forms of chemotherapy which are associated with both favorable and unfavorable prognoses. CCDRT should be much more widely utilized in clinical oncology practice and as an integral component of ongoing and future clinical trials.

Return to Human Tumor Assay Joural (HTAJ)  Home Page
Go to Introduction
Go to Chapter 1: Cell Proliferation Assays
Go to Chapter 2: Cell Death Assays
Go to Chapter 3: Correlations between assay results and clinical response
Go to Chapter 4: Assay results in the context of Bayes' Theorem
Go to Chapter 5: Specific diseases/Hematologics (ALL,ANLL,CLL,NHL)
Go to Chapter 6: Specific diseases/Solid Tumors (GI, Ovarian, Breast)
Go to Chapter 7: Editorial conclusions
Go to Literature Cited/Bibliography